Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

CHD1L Regulates Cell Survival in Breast Cancer and Its Inhibition by OTI-611 Impedes the DNA Damage Response and Induces PARthanatos.

Autor: Sala R; Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO 80045, USA., Esquer H; Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO 80045, USA.; The CU Anschutz Center for Drug Discovery, Aurora, CO 80045, USA.; The University of Colorado Cancer Center, The University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Kellett T; Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO 80045, USA., Kearns JT; Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO 80045, USA., Awolade P; Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO 80045, USA., Zhou Q; Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO 80045, USA.; The CU Anschutz Center for Drug Discovery, Aurora, CO 80045, USA.; The University of Colorado Cancer Center, The University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., LaBarbera DV; Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO 80045, USA.; The CU Anschutz Center for Drug Discovery, Aurora, CO 80045, USA.; The University of Colorado Cancer Center, The University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2024 Aug 06; Vol. 25 (16). Date of Electronic Publication: 2024 Aug 06.

The validation of new CHD1L inhibitors as a therapeutic strategy for cancer.

Autor: Clune S; The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, The University of Colorado (CU) Anschutz Medical Campus, Aurora, CO 80045, USA., Awolade P; The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, The University of Colorado (CU) Anschutz Medical Campus, Aurora, CO 80045, USA; The CU Anschutz Center for Drug Discovery, USA., Zhou Q; The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, The University of Colorado (CU) Anschutz Medical Campus, Aurora, CO 80045, USA; The CU Anschutz Center for Drug Discovery, USA; The CU Cancer Center, USA., Esquer H; The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, The University of Colorado (CU) Anschutz Medical Campus, Aurora, CO 80045, USA; The CU Anschutz Center for Drug Discovery, USA; The CU Cancer Center, USA., Matter B; The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, The University of Colorado (CU) Anschutz Medical Campus, Aurora, CO 80045, USA., Kearns JT; The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, The University of Colorado (CU) Anschutz Medical Campus, Aurora, CO 80045, USA., Kellett T; The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, The University of Colorado (CU) Anschutz Medical Campus, Aurora, CO 80045, USA., Akintayo DC; The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, The University of Colorado (CU) Anschutz Medical Campus, Aurora, CO 80045, USA., Kompella UB; The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, The University of Colorado (CU) Anschutz Medical Campus, Aurora, CO 80045, USA; The CU Anschutz Center for Drug Discovery, USA; The CU Cancer Center, USA., LaBarbera DV; The Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, The University of Colorado (CU) Anschutz Medical Campus, Aurora, CO 80045, USA; The CU Anschutz Center for Drug Discovery, USA; The CU Cancer Center, USA. Electronic address: daniel.labarbera@cuanschutz.edu.

Publikováno v: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Jan; Vol. 170, pp. 116037. Date of Electronic Publication: 2023 Dec 20.

Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer.

Autor: Zhu J; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Livasy C; Carolinas Pathology Group, Charlotte, NC, USA., Donahue EE; Department of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC, USA., Symanowski JT; Department of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC, USA., Grigg CM; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Brown LC; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Matulay JT; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Kearns JT; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Raghavan D; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Burgess EF; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Clark PE; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

Publikováno v: Translational andrology and urology [Transl Androl Urol] 2023 Feb 28; Vol. 12 (2), pp. 228-240. Date of Electronic Publication: 2023 Feb 07.

Moving Prostate Cancer Polygenic Risk Scores from Research Towards Clinical Practice.

Autor: Kearns JT; Levine Cancer Institute, Charlotte, NC, USA. Electronic address: james.kearns@atriumhealth.org., Helfand BT; Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA; Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, IL, USA., Xu J; Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA; Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, IL, USA.

Publikováno v: European urology focus [Eur Urol Focus] 2022 Jul; Vol. 8 (4), pp. 913-915. Date of Electronic Publication: 2022 Aug 31.